Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 2,523,949 |
|
|||||
| News | - | ||||||
| Day High | 16.71 | Low High |
|||||
| Day Low | 15.44 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Nurix Therapeutics Inc | NRIX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -1.28 | -7.65% | 15.46 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.71 | 15.44 | 16.71 | 15.46 | 16.74 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 25,178 | 2,523,949 | $ 15.95 | $ 40,252,431 | - | 4.22 - 18.12 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:14:59 | 20 | $ 15.57 | USD |
Nurix Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 755.41M | 48.89M | - | 76.99M | -143.95M | -2.94 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Nurix Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRIX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.12 | 18.12 | 13.46 | 16.41 | 2,188,922 | 1.34 | 9.49% |
| 1 Month | 13.10 | 18.12 | 12.26 | 15.14 | 1,155,101 | 2.36 | 18.02% |
| 3 Months | 8.24 | 18.12 | 7.65 | 12.90 | 927,906 | 7.22 | 87.62% |
| 6 Months | 6.44 | 18.12 | 4.22 | 10.33 | 851,943 | 9.02 | 140.06% |
| 1 Year | 12.37 | 18.12 | 4.22 | 10.08 | 592,842 | 3.09 | 24.98% |
| 3 Years | 30.27 | 37.425 | 4.22 | 15.19 | 470,070 | -14.81 | -48.93% |
| 5 Years | 20.25 | 52.38 | 4.22 | 17.72 | 437,541 | -4.79 | -23.65% |
Nurix Therapeutics Description
| Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |
